NCT05826275View on ClinicalTrials.gov

Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

May 28, 2025

Study Completion Date

June 28, 2025

Conditions
HPV Associated Cancers
Interventions
DRUG

TGN-S11

Small Molecule

DRUG

Pembrolizumab

PD-1 checkpoint blockade

Trial Locations (5)

10128

Icahn School of Medicine at Mount Sinai, New York

77030

MD Anderson Cancer Center, Houston

91010

City of Hope, Duarte

92093

UCSD Moores Cancer Center, La Jolla

06511

Yale University, New Haven

All Listed Sponsors
lead

Toragen, Inc.

INDUSTRY

NCT05826275 - Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer | Biotech Hunter | Biotech Hunter